NewGen Reports Fiscal 2025 Performance and Advances in Strategic Initiatives

(SeaPRwire) –   NewGen reports a robust balance sheet featuring total assets of US$32.7 million

Net profit attributable to the Company’s shareholders amounts to US$9.9 million

BANGKOK, May 4, 2026 — NewGenIVF Group (NASDAQ: NIVF) (“NewGen” or the “Company”), a tech-powered, diversified growth firm, today shared key highlights from its fiscal year 2025 performance and the consistent advancement of its ongoing strategic transformation.

Additional details about NewGen’s results are available in the Company’s Form 20-F annual report for the fiscal year ending December 31, 2025 (the “2025 Annual Report”), filed with the U.S. Securities and Exchange Commission (the “SEC”) in April 2026. The complete 2025 Annual Report is accessible on the Company’s investor relations website at https://investors.newgenivf.com/financials/annual-reports.

Key Financial and Operating Highlights

• Total assets as of December 31, 2025, stood at US$32.7 million, up from US$3.6 million as of December 31, 2024. This translates to total assets per share of US$135.9 as of December 31, 2025.
• Net profit attributable to the Company’s shareholders for the year ending December 31, 2025, was US$9.9 million, mainly driven by bargain purchase gains from the acquisition of the Company’s Nodexus and Microsort operations.
• In July 2025, the Company finalized the acquisition of advanced cytometry intellectual property, which was later independently valued at US$17.9 million by a Big Four accounting firm, resulting in a total bargain purchase gain of US$19.2 million.
• In November 2025, the Company approved a US$2 million share repurchase program, underscoring management’s confidence in the Company’s inherent value.
• The Company made further strides in the advancement of its diversification efforts, including digital asset innovation via NewGenDigital and health supplements through NewGenSup.

Mr. Siu Wing Fung Alfred, Founder, Chairman, and CEO of NewGen, stated: “Our fiscal year 2025 results showcase the successful implementation of our ongoing strategic transformation. With total assets exceeding US$32 million and a substantial profit for the fiscal year, we’ve proven that our diversification strategy is yielding concrete outcomes. We stay committed to creating long-term shareholder value and believe our current financial standing and growth path offer a solid base for sustained success.”

About NewGen

NewGenIVF Group is a tech-focused, diversified, multi-country high-growth organization that taps into emerging opportunities across real estate development, digital asset innovation, and reproductive health solutions. The Company operates three strategic business units that leverage state-of-the-art technology and creative solutions to drive sustainable growth and high returns for shareholders in various global markets. These include “NewGenProperty”, launched to explore and manage profitable real estate projects in the UAE’s Ras Al Khaimah Emirate; “NewGenDigital”, the Company’s digital asset and DeFi solutions branch; and “NewGenSup”, which specializes in health and longevity products and services. NewGen’s legacy business provides industry-leading IVF and assisted reproductive care across Asia. With operations spanning multiple countries and a dedication to innovative, tech-driven solutions, NewGenIVF Group is uniquely positioned to seize opportunities from the intersection of real estate, healthcare, and digital assets in the evolving global economy.

For more information, visit www.nivf.global. The content on or accessible via NewGen’s website is not incorporated by reference into this press release, and should not be regarded as part of this document.

Forward-Looking Statements

This press release includes forward-looking statements that reflect the Company’s current expectations and projections for future events. These may cover, but are not limited to, statements about the Company’s strategic transformation and diversification efforts; the integration and expected impact of the Nodexus and Microsort businesses, as well as the value of the acquired cytometry intellectual property; the growth and development of the Company’s digital asset innovation arm (NewGenDigital) and health supplements business (NewGenSup); the Company’s projected future financial performance, asset size, and profitability; the rollout of the Company’s share repurchase program; and the Company’s goals to build long-term shareholder value. Forward-looking statements are often marked by terms like “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “project,” “seek,” “target,” “will,” and similar phrases or their negatives—though not all such statements use these identifiers. These statements are based on management’s current beliefs, assumptions, and expectations, and involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ significantly from those implied or stated in the forward-looking statements. These risks include, but are not limited to: challenges related to integrating the Nodexus and Microsort businesses and the Company’s ability to realize the expected benefits of those acquisitions; the accuracy of estimates and assumptions used to calculate the bargain purchase gain and the fair value of the acquired intellectual property; risks tied to the Company’s diversification into digital asset innovation and health supplements, including the changing regulatory landscape for these sectors; the timing, amount, and execution of share repurchases (which may be adjusted, paused, or stopped at any time); the Company’s ability to expand its asset base and enhance operational performance; and the Company’s capacity to execute its strategic plans, along with other risk factors outlined in the Company’s public disclosures from time to time—including the Form 20-F annual report for the fiscal year ending December 31, 2025. Readers are advised not to rely excessively on forward-looking statements, which are valid only as of the date of this press release. The Company does not commit to updating or revising any forward-looking statements, whether due to new information, future events, or other reasons, unless required by applicable securities regulations.

Investor Relations Contact
ICR, LLC
Robin Yang
Phone: +1 (212) 537-3847
Email: NewgenivfIR@icrinc.com